People with HIV who took the older formulation of tenofovir with emtricitabine during 2020 had a substantially lower risk of hospital admission due to COVID-19 than people taking the new formulation of tenofovir or abacavir/lamivudine, a large Spanish study has reported.
However, the effect was only clear-cut in people aged 50 and over, probably due to the small number of cases of severe illness requiring hospital treatment in the under-50s.
Read the full story at Aidsmap.
Source : Aidsmap
Related HIV and Co-Infections News
-
ACTG launches landmark study evaluating treatments for depressive disorders with or without mild neurocognitive disorder among people living with HIV
-
Florida International University: HIV disrupts lung “clock,” raising COPD and emphysema risk
-
ESCMID: HIV treatment reduces accelerated biological aging by nearly four years, landmark study shows
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.